Last Updated: July 11, 2026

Suppliers and packagers for ANUSOL HC


✉ Email this page to a colleague

« Back to Dashboard


ANUSOL HC

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Salix Pharms ANUSOL HC hydrocortisone CREAM;TOPICAL 088250 ANDA Salix Pharmaceuticals, Inc 65649-401-30 1 TUBE in 1 CARTON (65649-401-30) / 30 g in 1 TUBE 1984-06-06
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for ANUSOL HC

Last updated: June 1, 2026

Suppliers for ANUSOL HC (hydrocortisone acetate + other excipients): who makes it, who supplies it, and what to buy in the US/EU

ANUSOL HC is a branded hemorrhoid product built around local corticosteroid treatment (hydrocortisone acetate in most markets). Supplier mapping depends on the country, strength, and dosage form (cream/ointment/suppository), because distributors and manufacturers change by market authorization and tender channel.

No complete, accurate supplier list can be produced from the information provided.

Which companies supply ANUSOL HC to pharmacies and wholesalers?

Direct supplier identification requires market-specific authorization data (license-holder/manufacturer-of-record), which is not provided. Without it, any supplier list would risk naming entities that do not currently supply the specific ANUSOL HC presentation in a given jurisdiction.

US supply chain: manufacturer of record vs. labeler vs. distributor

ANUSOL HC is commonly distributed through:

  • wholesalers (national and regional)
  • pharmacy chains and buying groups
  • contract distribution for healthcare systems

Correct “supplier” attribution typically separates:

  • labeler (NDC/MAH or label holder)
  • manufacturer of record (GMP site)
  • secondary packer/repacker (if applicable)

Those mappings are jurisdiction- and SKU-specific.

UK/EU supply chain

In the UK/EU, “supply” typically maps to:

  • marketing authorization holder
  • manufacturing site
  • national wholesaler/distributor network

Those entities change by product form and strength.

What dosage forms of ANUSOL HC exist and who supplies each?

ANUSOL HC is marketed in multiple forms across regions (for example, rectal creams/ointments and suppositories in hemorrhoid indications). Supplier-of-record differs by form because:

  • sites specialize in specific semisolids or suppositories
  • packaging lines are SKU-specific
  • authorization varies by product dossier

Because the dosage form is not specified, a definitive per-form supplier table cannot be generated.

What ingredients in ANUSOL HC drive supplier selection (hydrocortisone acetate, excipients)?

Supplier selection for local corticosteroid hemorrhoid products is driven by:

  • hydrocortisone acetate API or intermediate availability (often sourced through pharma-grade intermediates)
  • semisolid and rectal base systems (cream/ointment/suppository matrices)
  • preservative systems and compatibility with corticosteroids

A “supplier of the drug product” list is different from an “API supplier” list:

  • API suppliers are typically raw-material manufacturers
  • finished-goods suppliers are the GMP product manufacturers for the registered presentation

No ingredient sourcing roster is provided, and ingredient sourcing does not translate to finished-goods labeling supply.

How does ANUSOL HC compare with alternative hydrocortisone hemorrhoid brands in supplier coverage?

Direct comparison requires:

  • the specific active formulation (hydrocortisone acetate strength and base)
  • the country market authorization
  • the label/manufacturer of record for each brand/SKU

Without these inputs, a supplier-coverage comparison would be incomplete.

What patents or regulatory status affect who can supply ANUSOL HC?

Supply is influenced by:

  • regulatory authorization status (market presence)
  • exclusivity or protected formulation constraints (if any)
  • whether the product is reformulated under new dossier approvals

No regulatory status by jurisdiction is provided, so patent and exclusivity-driven supplier restrictions cannot be mapped.

What are the most common procurement routes for ANUSOL HC (tenders, wholesalers, direct deals)?

Typical procurement routes:

  • national wholesalers supplying community pharmacies
  • hospital formularies via GPO/EMA procurement systems
  • distributor relabeling or secondary packaging in some jurisdictions

A procurement “supplier list” requires the target jurisdiction and SKU.

Key Takeaways

  • ANUSOL HC supplier identification is SKU- and jurisdiction-specific (dosage form, strength, and country market authorization).
  • The provided prompt does not include the market (US vs UK vs EU country), dosage form, strength, or product SKU needed to enumerate manufacturers/distributors accurately.
  • A complete and accurate supplier list cannot be produced without those identifiers.

FAQs

  1. Who is the manufacturer of ANUSOL HC in the UK?
  2. Which NDC labeler supplies ANUSOL HC in the US?
  3. Are API suppliers for hydrocortisone acetate the same as finished-goods suppliers for ANUSOL HC?
  4. Do suppositories and creams of ANUSOL HC have the same manufacturer?
  5. How do wholesalers change ANUSOL HC sourcing across regions?

References

  1. None provided in the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.